321 related articles for article (PubMed ID: 28417905)
1. Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases.
Sabatino R; Perrone A; Cuomo M; Liotti S; Barchiesi V; Cantile M; Cavalcanti E
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417905
[TBL] [Abstract][Full Text] [Related]
2. Serum free light chains in clinical laboratory diagnostics.
Jenner E
Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
[TBL] [Abstract][Full Text] [Related]
3. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
[TBL] [Abstract][Full Text] [Related]
5. [Comparative analysis of immunoglobulin free light chains quantification by Freelite™ (The Binding Site) and N Latex FLC (Siemens) methods].
Schneider N; Wynckel A; Kolb B; Sablon E; Gillery P; Maquart FX
Ann Biol Clin (Paris); 2013; 71(1):13-9. PubMed ID: 23396425
[TBL] [Abstract][Full Text] [Related]
6. Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory.
Caponi L; Romiti N; Koni E; Fiore AD; Paolicchi A; Franzini M
Crit Rev Clin Lab Sci; 2020 Mar; 57(2):73-85. PubMed ID: 31612753
[TBL] [Abstract][Full Text] [Related]
7. Serum-free light-chain assay: clinical utility and limitations.
Bhole MV; Sadler R; Ramasamy K
Ann Clin Biochem; 2014 Sep; 51(Pt 5):528-42. PubMed ID: 24489083
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
9. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
[TBL] [Abstract][Full Text] [Related]
10. Application of Capillary Electrophoresis in Monoclonal Gammopathies and the Cutoff Value of Monoclonal Protein in Differential Diagnosis of Multiple Myeloma and Other Monoclonal Gammopathies.
Cao F; Zhang R; Xu L; Liu M; Yuan Y
Ann Clin Lab Sci; 2021 May; 51(3):400-407. PubMed ID: 34162571
[TBL] [Abstract][Full Text] [Related]
11. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias.
Mayo MM; Johns GS
Contrib Nephrol; 2007; 153():44-65. PubMed ID: 17075223
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
13. [Free light chains assay: Indications and methods].
Martellosio JP; Leleu X; Roblot P; Martin M; Puyade M
Rev Med Interne; 2019 May; 40(5):297-305. PubMed ID: 30862366
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy.
Wolff F; Thiry C; Willems D
Clin Biochem; 2007 Mar; 40(5-6):351-4. PubMed ID: 17239359
[TBL] [Abstract][Full Text] [Related]
15. [Clinical usefulness of serum free light chain measurement in monoclonal gammopathy].
Shimazaki C; Murakami H; Sawamura M; Matsuda M; Kinoshita T; Hata H; Sugiura I; Tsushita K; Nagura E; Kosugi H; Itoh J; Shimizu K
Rinsho Ketsueki; 2010 Apr; 51(4):245-52. PubMed ID: 20467220
[TBL] [Abstract][Full Text] [Related]
16. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
Milani P; Palladini G; Merlini G
Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897
[TBL] [Abstract][Full Text] [Related]
17. [Determination of light chains in serum].
Hansen CT; Nielsen L; Münster AM; Abildgaard N
Ugeskr Laeger; 2010 Aug; 172(34):2302-5. PubMed ID: 20727297
[TBL] [Abstract][Full Text] [Related]
18. The association of serum-free light-chain levels with markers of renal function.
Erdem BK; Davran F; Yilmaz VT; Çetinkaya R; Akbas H
Ren Fail; 2015 Jul; 37(6):1057-60. PubMed ID: 26056734
[TBL] [Abstract][Full Text] [Related]
19. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine.
Campbell JP; Cobbold M; Wang Y; Goodall M; Bonney SL; Chamba A; Birtwistle J; Plant T; Afzal Z; Jefferis R; Drayson MT
J Immunol Methods; 2013 May; 391(1-2):1-13. PubMed ID: 23388695
[TBL] [Abstract][Full Text] [Related]
20. Clinical and preclinical validation of the serum free light chain assay: identification of the critical difference for optimized clinical use.
Hansen CT; Münster AM; Nielsen L; Pedersen P; Abildgaard N
Eur J Haematol; 2012 Dec; 89(6):458-68. PubMed ID: 22998393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
